Comparative Pharmacology
Head-to-head clinical analysis: MENTAX TC versus OXICONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX TC versus OXICONAZOLE NITRATE.
MENTAX-TC vs OXICONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
Oxiconazole nitrate is an azole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This leads to increased membrane permeability and cell death.
Apply a thin layer to affected area once daily for 2-4 weeks.
Apply a thin layer to affected skin once daily for 2 weeks for tinea pedis, tinea cruris, and tinea corporis.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
Terminal elimination half-life is approximately 20-30 hours, allowing once-daily or twice-daily topical application.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Primarily biliary/fecal: >75% of dose excreted unchanged and as metabolites in feces via bile; renal excretion accounts for <10% (mostly inactive metabolites).
Category C
Category C
Topical Antifungal
Topical Antifungal